Figure 3: RhCMV/EBOV-GP induces high levels of EBOV GP-specific antibodies with absence of GP-directed T cell responses in NHPs. | Scientific Reports

Figure 3: RhCMV/EBOV-GP induces high levels of EBOV GP-specific antibodies with absence of GP-directed T cell responses in NHPs.

From: Cytomegalovirus-based vaccine expressing Ebola virus glycoprotein protects nonhuman primates from Ebola virus infection

Figure 3

(A) Schematic showing timeline of ‘vaccine’ and ‘challenge’ phases and sampling schedule. (B) Time course of CD4+ and CD8+ T cell responses against IE-1, pRh112 (pp65b) and GP. T cells were analyzed by ICS following incubation with overlapping peptide pools in the presence of brefeldin (A). Levels of responding cells (TNFα and IFNγ double-positive) in individual NHPs are shown at indicated time points. T cell responses against endogenous RhCMV antigens (IE-1 and Rh112) were observed in all animals, while no responses against GP were detected at any time. (C) Time course of antibody responses against EBOV GP. Total EBOV GP-specific IgG levels were measured by ELISA at indicated time points. (D) RhCMV-specific antibody levels prior to vaccination. Presence of RhCMV-specific antibodies prior to vaccination (pre-bleed samples) indicates that all NHPs were RhCMV seropositive as a result of natural RhCMV infection at the time of initial vaccination.

Back to article page